Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
暂无分享,去创建一个
Y. Hiasa | O. Yoshida | M. I. Khan | M. Al Mahtab | F. Begum | S. M. Akbar | A. Shrestha | S. S. Hossain | Sukumar Sarker | S. A. S. Hossain
[1] G. Gartlehner,et al. [Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy]. , 2022, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).
[2] P. Ashok Kumar,et al. Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[3] S. Chunsuttiwat,et al. Progress Toward Hepatitis B Control — South-East Asia Region, 2016–2019 , 2020, MMWR. Morbidity and mortality weekly report.
[4] Yared Tadesse,et al. Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation , 2020, Cost Effectiveness and Resource Allocation.
[5] M. Hellard,et al. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. , 2020, The Lancet. Global health.
[6] M. Kumar,et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission , 2019, The Lancet Gastroenterology & Hepatology.
[7] P. Parija,et al. Hepatitis B vaccine birth dose in India: time to reconsider , 2020, Human vaccines & immunotherapeutics.
[8] K. Ueda,et al. A meta-analysis on genetic variability of RT/HBsAg overlapping region of hepatitis B virus (HBV) isolates of Bangladesh , 2019, Infectious Agents and Cancer.
[9] H. Janssen,et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study) , 2019, Gut.
[10] Zhengming Chen,et al. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people , 2019, BMJ Open.
[11] C. Staton,et al. Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies , 2019, Conflict and Health.
[12] Y. Hiasa,et al. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial) , 2018, PloS one.
[13] Minal K. Patel,et al. Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries , 2018, Journal of immunological sciences.
[14] F. Zoulim,et al. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. , 2018, Current opinion in virology.
[15] D. Smith,et al. Occult HBV infection in HIV‐infected adults and evaluation of pooled NAT for HBV , 2018, Journal of viral hepatitis.
[16] V. Wong,et al. Eliminating hepatitis B virus as a global health threat. , 2016, The Lancet. Infectious diseases.
[17] O. Opare-Sem,et al. Screening and diagnosis of HBV in low-income and middle-income countries , 2016, Nature Reviews Gastroenterology &Hepatology.
[18] Chien-Jen Chen,et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. , 2016, Gastroenterology.
[19] J. Alexander,et al. Hepatitis B control among children in the Eastern Mediterranean Region of the World Health Organization. , 2016, Vaccine.
[20] Y. Poovorawan,et al. The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation , 2016, PloS one.
[21] M. Manglani,et al. A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine , 2015, Human vaccines & immunotherapeutics.
[22] Xiaomao Li,et al. Mother‐to‐child transmission of HBV: review of current clinical management and prevention strategies , 2014, Reviews in medical virology.
[23] S. Rahman,et al. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B , 2013, Hepatology International.
[24] K. Narayanswamy. Hepatitis B and pregnancy: challenges in India. , 2011, Journal of the Indian Medical Association.
[25] J. Dienstag. Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.
[26] S. Chakrabarti,et al. Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[27] A. Sutanto,et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. , 2007, Vaccine.
[28] T. Poynard,et al. Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants , 2006, Journal of Virology.
[29] Y. Hiasa,et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[30] A. Theamboonlers,et al. Variants within the "a" determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI). , 2001, The Tohoku journal of experimental medicine.
[31] A. Zuckerman,et al. HEPATITIS B VARIANT IN EUROPE , 1988, The Lancet.